Effect of Soleus Muscle Kinetic Control Training on Gait and Electromyographic Activity in Patients With Stroke (EMG)

this study was designed to investigate the effect of soleus muscle kinetic control training on Gait and electromyographic activity of the calf muscle in patients with stroke

Study Overview

• Status: Not yet recruiting
• Conditions: Stroke
• Intervention / Treatment: Other: soleus kinetic control; Other: conventional therapy

Detailed Description

Stroke is a neurological condition characterized by a reduced blood supply to the brain tissue, resulting in paralysis of part or all of the body, limiting physical activity and social participation. Gait impairment accounts for the largest proportion of physical activity limitations in stroke patients and is characterized by muscle weakness, foot drop, spasticity, and foot deformity .Gait abnormalities following stroke are often disabling. Reduced ankle dorsiflexion, knee flexion, or hip flexion torques are often postulated causes of compromised toe clearing during the swing phase of gait. conversely, gait asymmetry and reduced walking speed has been attributed to weakness of the planter flexors.The kinetic control comprises balanced presentation of the movement choices with ideal interaction among the key components for the sensorimotor neuromuscular control that mediated by afferent sensory input, particularly the proprioceptive input, CNS integration, optimal motor co-ordination, and physiological stresses to assure functional dynamic stability and controlled mobility. forty patients with stroke will be assigned to two groups; one group will recieve kinetic control plus conventional therapy and control group will receive conventinoal therapy alone.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: habiba mohamed, master; Phone Number: 0 10 90708377; Email: dochabiba4@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Ischemic or hemorrhagic stroke, as confirmed by CT and or MRI scan.
• Age of the patients between 45 to 60 years old.
• Ability to walk a minimum of 10 m with or without some physical assistance from a therapist (functional ambulation category more than 2).
• Demonstrate weakness of the foot muscles, measured by muscle function tests according Medical Research council scale more than 3.
• Muscle tone of the affected lower limb ranges from 1 to +1 according to modified Ashworth scale.

Exclusion Criteria:

• Unilateral neglect, hemianopia, or apraxia
• Having any other neurological disorder affecting their lower extremities e.g. MS, Parkinsonism, peripheral neuropathy.
• Patients with previous fractures in lower limb (Ankle or foot).
• Patients with musculoskeletal disorder such as severe arthritis, ankle surgery, leg length discrepancy or contractures of fixed deformity of ankle joint.
• Patients with visual, auditory impairment affecting their ability to complete tasks.
• Patients with cognitive impairments

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: soleus kinetic control; twenty patients will receive soleus kinetic control plus conventional physiotherapy three times a week for 8 weeks	Other: soleus kinetic control; patients will receive kinetic control for 30 minutes structural progressive training for the soleus muscle guided by the EMG biofeedback plus conventional therapy; 1)Start in crook lying position with the heels level with the pelvis and lift the pelvis clear of the floor followed by bilateral heel raise,2)Progress further by shifting weight onto one leg and holding the heel raise and slowly lowering eccentrically on 1 foot, the next progression is to perform the same movement with the heels lower than the pelvis on step -below the pelvis. The exercise graduation will be guided by the visual EMG Biofeedback participants will receive feedback on soleus activation throughout the training.; Other: conventional therapy; the patients will receives conventional physiotherapy program static stretching and stretching board for calf muscle, stretching board, and push off exercises by having the patient push against the therapist or a treatment table during forward gait ( 30 minute), static stretch(30sec\set , rest 20sec\set total 5 set, 3 times \week , for 8 week ), stretching board (4 min\set , rest 1 min\set total 2 set , 3 times \week , for 8 week ) (10 minute) push off training (15 minute 3 times \week , for 8 week )x2
Active Comparator: conventional therapy; twenty patients will receive conventional physiotherapy three times a week for 8 weeks	Other: conventional therapy; the patients will receives conventional physiotherapy program static stretching and stretching board for calf muscle, stretching board, and push off exercises by having the patient push against the therapist or a treatment table during forward gait ( 30 minute), static stretch(30sec\set , rest 20sec\set total 5 set, 3 times \week , for 8 week ), stretching board (4 min\set , rest 1 min\set total 2 set , 3 times \week , for 8 week ) (10 minute) push off training (15 minute 3 times \week , for 8 week )x2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
muscle amplitude	A steady device will be used to assess muscle amplitude in the form of RMS with microvolt as the measurement unit	up to eight weeks
giat function	The Dynamic Gait Index (DGI) is an ordinal test of gait function evaluates the capacity to adapt gait to complex walking tasks encountered in everyday life. Eight aspects of gait are scored based on observation as the patient walks over a 6.1-m level surface. The rater records an ordinal score that ranges from 0 (unable or done very poorly) to 3 (normal score) for a total point value of 24. Scores of less than 21 appear to suggest risk for falls	up to eight weeks
Gait Cycle time	time of gait cycle (seconds) will be measured by steady device	up to eight weeks
step time	the time of step by seconds will be measured by steady device	up to eight weeks
cadence	Cadence, number of steps per minute, will be measured by steady device	up to eight weeks
stance phase percentage	the percentage of stance phase will be measured by steady device	up to eight weeks
swing phase percentage	the percentage of swing phase will be measured by steady device	up to eight weeks
single and double support percentage	single and double support percentage of gait cycle will be measured by steady device	up to eight weeks
first and second double support percentage	first and second double support percentage of gait cycle will be measured by steady devcie	up to eight weeks
stride length	stride length by cm will be measured by steady device	up to eight weeks
gait speed	gait speed by km/h will measured by steady device	up to eight weeks

Collaborators and Investigators

• Sponsor: Cairo University

Study record dates

Study Major Dates

• Study Start (Estimated): December 15, 2025
• Primary Completion (Estimated): June 15, 2026
• Study Completion (Estimated): June 15, 2026

Study Registration Dates

• First Submitted: December 1, 2025
• First Submitted That Met QC Criteria: December 15, 2025
• First Posted (Actual): December 30, 2025

Study Record Updates

• Last Update Posted (Actual): December 30, 2025
• Last Update Submitted That Met QC Criteria: December 15, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: stroke; gait; EMG; kinetic control
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke
• Other Study ID Numbers: P.T.REC/012/006089

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No